PL2237783T3 - Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibu - Google Patents
Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibuInfo
- Publication number
- PL2237783T3 PL2237783T3 PL09704256T PL09704256T PL2237783T3 PL 2237783 T3 PL2237783 T3 PL 2237783T3 PL 09704256 T PL09704256 T PL 09704256T PL 09704256 T PL09704256 T PL 09704256T PL 2237783 T3 PL2237783 T3 PL 2237783T3
- Authority
- PL
- Poland
- Prior art keywords
- imatinib
- optimizing
- treatment
- tyrosine kinase
- proliferative diseases
- Prior art date
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title 1
- 229960002411 imatinib Drugs 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2294508P | 2008-01-23 | 2008-01-23 | |
| PCT/US2009/031510 WO2009094360A1 (en) | 2008-01-23 | 2009-01-21 | Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib |
| EP09704256.8A EP2237783B1 (en) | 2008-01-23 | 2009-01-21 | Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2237783T3 true PL2237783T3 (pl) | 2015-04-30 |
Family
ID=40435094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09704256T PL2237783T3 (pl) | 2008-01-23 | 2009-01-21 | Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibu |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20100298338A1 (enExample) |
| EP (1) | EP2237783B1 (enExample) |
| JP (2) | JP5936821B2 (enExample) |
| KR (1) | KR101579993B1 (enExample) |
| CN (1) | CN101951910B (enExample) |
| AU (1) | AU2009206566A1 (enExample) |
| BR (1) | BRPI0906504A2 (enExample) |
| CA (1) | CA2712087A1 (enExample) |
| ES (1) | ES2526537T3 (enExample) |
| MX (1) | MX2010008103A (enExample) |
| PL (1) | PL2237783T3 (enExample) |
| PT (1) | PT2237783E (enExample) |
| RU (1) | RU2537223C2 (enExample) |
| WO (1) | WO2009094360A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2753391C1 (ru) * | 2020-09-29 | 2021-08-13 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0127922D0 (en) * | 2001-11-21 | 2002-01-16 | Novartis Ag | Organic compounds |
| SI1686997T1 (sl) * | 2003-11-18 | 2009-08-31 | Novartis Ag | Inhibitorji mutantne oblike KIT |
| US7329495B2 (en) * | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| EP2251042A3 (en) * | 2006-09-22 | 2012-05-02 | Novartis AG | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
| CA2668828A1 (en) | 2006-11-07 | 2008-05-29 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
-
2009
- 2009-01-21 EP EP09704256.8A patent/EP2237783B1/en not_active Revoked
- 2009-01-21 US US12/863,627 patent/US20100298338A1/en not_active Abandoned
- 2009-01-21 MX MX2010008103A patent/MX2010008103A/es active IP Right Grant
- 2009-01-21 BR BRPI0906504-0A patent/BRPI0906504A2/pt not_active IP Right Cessation
- 2009-01-21 PL PL09704256T patent/PL2237783T3/pl unknown
- 2009-01-21 CN CN2009801027282A patent/CN101951910B/zh not_active Expired - Fee Related
- 2009-01-21 JP JP2010544393A patent/JP5936821B2/ja not_active Expired - Fee Related
- 2009-01-21 CA CA2712087A patent/CA2712087A1/en not_active Abandoned
- 2009-01-21 KR KR1020107018386A patent/KR101579993B1/ko not_active Expired - Fee Related
- 2009-01-21 RU RU2010134916/15A patent/RU2537223C2/ru not_active IP Right Cessation
- 2009-01-21 AU AU2009206566A patent/AU2009206566A1/en not_active Abandoned
- 2009-01-21 PT PT97042568T patent/PT2237783E/pt unknown
- 2009-01-21 ES ES09704256.8T patent/ES2526537T3/es active Active
- 2009-01-21 WO PCT/US2009/031510 patent/WO2009094360A1/en not_active Ceased
-
2013
- 2013-12-18 JP JP2013261728A patent/JP5881671B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-27 US US14/924,207 patent/US20160045501A1/en not_active Abandoned
-
2016
- 2016-10-19 US US15/297,372 patent/US9763944B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2237783B1 (en) | 2014-11-19 |
| PT2237783E (pt) | 2014-12-23 |
| AU2009206566A1 (en) | 2009-07-30 |
| CA2712087A1 (en) | 2009-07-30 |
| US20170035757A1 (en) | 2017-02-09 |
| CN101951910A (zh) | 2011-01-19 |
| WO2009094360A1 (en) | 2009-07-30 |
| JP2011510086A (ja) | 2011-03-31 |
| JP2014094946A (ja) | 2014-05-22 |
| RU2537223C2 (ru) | 2014-12-27 |
| US9763944B2 (en) | 2017-09-19 |
| RU2010134916A (ru) | 2012-02-27 |
| ES2526537T3 (es) | 2015-01-13 |
| EP2237783A1 (en) | 2010-10-13 |
| JP5881671B2 (ja) | 2016-03-09 |
| US20100298338A1 (en) | 2010-11-25 |
| KR20100105778A (ko) | 2010-09-29 |
| JP5936821B2 (ja) | 2016-06-22 |
| CN101951910B (zh) | 2013-07-17 |
| KR101579993B1 (ko) | 2015-12-23 |
| MX2010008103A (es) | 2010-08-23 |
| US20160045501A1 (en) | 2016-02-18 |
| BRPI0906504A2 (pt) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2960A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| IL206544A0 (en) | Methods of preparing quinazolinone derivatives | |
| IL212986A0 (en) | Methods for treating eye disorders | |
| ZA200906210B (en) | 3-Imidazolyl-Indoles for the treatment of proliferative diseases | |
| IL212412A0 (en) | Femto-cell location by direct methods | |
| ZA201201703B (en) | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors | |
| ZA201201592B (en) | Compounds as tyrosine kinase modulators | |
| EP2178369A4 (en) | TREATMENTS OF PROLIFERATIVE DISORDERS OF LYMPHOCYTES B | |
| PT2231642E (pt) | Pirimidinas como inibidores de quinase | |
| EP2350024A4 (en) | IMPROVED METHOD FOR THE PRODUCTION OF ENDOTHELIN RECEPTOR ANTAGONISTS | |
| GB0814152D0 (en) | Sleeve for trans-dermal patches | |
| IL207397A0 (en) | Difluorobiphenylamide derivtives for the treatment of ocular hypertension | |
| EP2475390A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS | |
| IL213607A0 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases | |
| EP2247185A4 (en) | INHIBITORS OF TYROSINE KINASE | |
| ZA201100759B (en) | Process for the preparation of substituted pyrimidine derivatives | |
| GB0818649D0 (en) | Treatment of proliferative disorders with trail | |
| SI2331098T1 (sl) | Postopki za dajanje iloperidona | |
| IL199839A0 (en) | Process for the manufacture of substituted 2-cyano cinnamic esters | |
| IL210558A0 (en) | Treatment of anxiety disorders | |
| PL2237783T3 (pl) | Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibu | |
| GB0807756D0 (en) | Central heating control apparatus | |
| SI2068938T1 (sl) | Optimizacija zdravljenja Philadelphia-pozitivne levkemije z inhibitorjem Abl tirozin kinaze imatinibom | |
| GB2461601B (en) | Adjustable template | |
| TWI319835B (en) | Brightness adjustment method |